Caregility has been ranked #1 in the 2021 Best in KLAS: Virtual Care Platforms (Non-EMR) report.
“We are honored to achieve the prestigious designation of 2021 Best in KLAS in our category,” said Ron Gaboury, CEO of Caregility. “2020 brought the crucial nature of virtual care to the forefront. We are grateful to play our part working alongside healthcare providers to ensure safe and effective care delivery, even in the most challenging of times. As we look ahead, virtual care will continue to play a fundamental role in enabling care with the right clinician, at the right time, and in the right location for patients. We look forward to bringing continued advancements to this important work.”
The Best in KLAS designation recognizes software and services companies who excel in helping healthcare professionals improve patient care. Rankings are a direct result of the feedback of thousands of providers over the last year. A Best in KLAS award signifies to the healthcare IT industry the commitment and partnership that top vendors provide.
Full rankings and details on 2021 Best in KLAS virtual care platforms may be viewed here.
“Each year, thousands of healthcare professionals across the globe take the time to share their voice with KLAS,” said Adam Gale, President of KLAS. ”They know that sharing their perspective helps vendors to improve and helps their peers make better decisions. These conversations are a constant reminder to me of how necessary accurate, honest, and impartial reporting is in the healthcare industry.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More